Lestaurtinib (former name, CEP‐701) is a tyrosine kinase inhibitor, that is multi‐targeted and was involved at nanomolar concentrations in potently inhibiting FLT3 in pre‐clinical studies, leading to its development as a potential targeted agent in acute myeloid leukaemia.26, 27. This evidence concerns the gene FLT3 and acute myeloid leukemia.